Dataset Information


Clinical relevance of circulating tumor DNA assessed through deep sequencing in patients with metastatic colorectal cancer.

ABSTRACT: Because circulating tumor DNA (ctDNA) studies focusing on only one or a few genes to monitor the disease progress or treatment response are unlikely to find its clinical significance, the development of cell-free DNA (cfDNA) panel covering hundreds of mutation hot spots is important for the establishment of clinically practical ctDNA detection system. We enrolled 101 patients with metastatic colorectal cancer (mCRC) who received chemotherapy. Amplicon-based genomic profiling of 14 genes, which are commonly mutated in CRC, in plasma by next-generation sequencing (NGS) was carried out to evaluate the feasibility of this assay and was compared with their clinical parameters and RAS status in matched tissue samples. Somatic mutations of the 14 genes in plasma cfDNA were detected in 88 patients (87.1%) with mCRC. Mutations in TP53, KRAS, and APC genes were detected in 70 (69.3%), 39 (38.6%), and 24 (23.7%) patients, respectively. Mutant allele frequencies in plasma were significantly associated with metastasis (liver, P = 0.00004, lymph node, P = 0.008, number of metastatic organs, P = 0.0006), tumor markers (CEA, P = 0.000007, CA19-9, P = 0.006, LDH, P = 0.00001), and tumor diameter (maximum, P = 0.00002, sum of diameter, P = 0.00009). The overall concordance rate of RAS status between ctDNA and matched tissue was 77.2% (78/101). Our data confirmed that mutant allele in cfDNA can be sensitively detected by amplicon-based NGS system. These results suggest that ctDNA could be a novel diagnostic biomarker to monitor changes in mutational status and tumor burden in patients with mCRC.

PROVIDER: S-EPMC6346227 | BioStudies |

REPOSITORIES: biostudies

Similar Datasets

2016-01-01 | S-EPMC5423131 | BioStudies
2019-01-01 | S-EPMC6759656 | BioStudies
2019-01-01 | S-EPMC6822250 | BioStudies
2018-01-01 | S-EPMC5863340 | BioStudies
2020-01-01 | S-EPMC7003348 | BioStudies
2018-01-01 | S-EPMC6085225 | BioStudies
1000-01-01 | S-EPMC5834035 | BioStudies
2017-01-01 | S-EPMC5834108 | BioStudies
2019-01-01 | S-EPMC6679157 | BioStudies
2020-01-01 | S-EPMC7378792 | BioStudies